Verastem Oncology, a biopharmaceutical company, appoints new leadership to drive growth in R&D and commercialization.
John Johnson appointed as Chairman of the Board and Michael Kauffman as President of Development.
Commercial launch progresses with completion of additional patient enrollment in RAMP 301 Phase 3 trial for recurrent LGSOC.
Strategic Leadership Changes
John Johnson appointed as Chairman of the Board, replacing Dr. Michael Kauffman who is now President of Development.
RAMP 301 Trial Update
RAMP 301 Phase 3 trial in recurrent LGSOC completed additional patient enrollment with topline data expected in mid-2027.
Departure of COO
Matthew Ros, Chief Operating Officer, to depart as company streamlines operational structure.
- The appointment of new leadership aims to accelerate Verastem's growth in developing new medicines for RAS/MAPK pathway-driven cancers.
- Completion of patient enrollment in RAMP 301 trial signifies progress towards potential treatment breakthroughs in rare ovarian cancer.
- Company restructuring signals a focused approach to enhance R&D and operational efficiency.
Verastem Oncology's strategic transitions position the company for future success in advancing cancer treatments, with a strong focus on research and commercialization under new leadership.